NantKwest, Inc. (NK) Given Consensus Recommendation of “Hold” by Analysts
Shares of NantKwest, Inc. (NASDAQ:NK) have earned an average rating of “Hold” from the six ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $5.13.
NK has been the subject of a number of recent research reports. Zacks Investment Research raised NantKwest from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a report on Wednesday, October 11th. Citigroup set a $3.00 target price on NantKwest and gave the stock a “sell” rating in a report on Monday, August 14th. Finally, BidaskClub downgraded NantKwest from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th.
Shares of NantKwest (NASDAQ:NK) opened at $4.83 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. NantKwest has a 12 month low of $2.71 and a 12 month high of $8.45.
In other news, Director Steve Gorlin sold 39,604 shares of NantKwest stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $5.93, for a total transaction of $234,851.72. Following the transaction, the director now directly owns 246,280 shares in the company, valued at approximately $1,460,440.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 70.19% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of NK. JPMorgan Chase & Co. boosted its position in shares of NantKwest by 155.8% in the third quarter. JPMorgan Chase & Co. now owns 25,579 shares of the biotechnology company’s stock worth $140,000 after buying an additional 71,444 shares during the period. SG Americas Securities LLC boosted its position in shares of NantKwest by 254.3% in the third quarter. SG Americas Securities LLC now owns 49,356 shares of the biotechnology company’s stock worth $270,000 after buying an additional 35,424 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of NantKwest in the third quarter worth $139,000. California State Teachers Retirement System boosted its position in NantKwest by 58.1% during the second quarter. California State Teachers Retirement System now owns 54,154 shares of the biotechnology company’s stock valued at $411,000 after purchasing an additional 19,900 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in NantKwest by 1,110.9% during the second quarter. The Manufacturers Life Insurance Company now owns 27,572 shares of the biotechnology company’s stock valued at $210,000 after purchasing an additional 25,295 shares during the last quarter. Institutional investors and hedge funds own 19.14% of the company’s stock.
Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.